TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

Deepa Joshi,1 Prashant GJ,1 Shohini Ghosh,1 Anookh Mohanan,1 Shashank Joshi,2 Viswanathan Mohan,3 Subhankar Chowdhury,4 Chaitanya Dutt,1 Nikhil Tandon5 1Torrent Pharmaceuticals Ltd., Ahmedabad, Gujarat, India; 2Lilavati Hospital, Mumbai, India; 3Dr. Mohan’s Diabetes Specialities Centre (Madras Diabe...

Full description

Bibliographic Details
Main Authors: Joshi D, GJ P, Ghosh S, Mohanan A, Joshi S, Mohan V, Chowdhury S, Dutt C, Tandon N
Format: Article
Language:English
Published: Dove Medical Press 2022-02-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
cardiometabolic-based chronic disease
mitochondrial modulator
type 2 diabetes
non-hdl cholesterol
hypertension
dyslipidemia.
Online Access:https://www.dovepress.com/trc150094-a-novel-mitochondrial-modulator-reduces-cardio-metabolic-ris-peer-reviewed-fulltext-article-DMSO

Internet

https://www.dovepress.com/trc150094-a-novel-mitochondrial-modulator-reduces-cardio-metabolic-ris-peer-reviewed-fulltext-article-DMSO

Similar Items